{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vasc:pharm:dapt-duration",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:26:00.000Z",
    "updated": "2026-01-07T03:26:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.92,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "treatment-duration",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "DAPT Duration in Peripheral Interventions",
    "description": "Duration of dual antiplatelet therapy after peripheral vascular interventions",
    "key_concepts": [
      {
        "concept": "After PTA Alone",
        "details": "Typically aspirin alone or 1-3 months DAPT; less evidence-based than coronary"
      },
      {
        "concept": "After Stenting",
        "details": "Generally 1-6 months DAPT; longer for drug-eluting stents; individualize by bleeding risk"
      },
      {
        "concept": "After Bypass",
        "details": "Aspirin lifelong; role of DAPT less clear; may add clopidogrel for poor targets"
      },
      {
        "concept": "COMPASS Trial",
        "details": "Rivaroxaban 2.5mg BID + aspirin superior to aspirin alone for PAD patients"
      }
    ],
    "clinical_significance": "Optimal duration remains uncertain; individualize based on ischemic/bleeding risk"
  },
  "provenance": {
    "primary_sources": ["Bonaca MP et al. J Am Coll Cardiol 2016"]
  }
}
